These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11811741)

  • 21. Emerging trends in Sjögren's syndrome: basic and translational research.
    Gallo A; Baldini C; Teos L; Mosca M; Bombardieri S; Alevizos I
    Clin Exp Rheumatol; 2012; 30(5):779-84. PubMed ID: 23009759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversal of Sjogren's-like syndrome in non-obese diabetic mice.
    Tran SD; Kodama S; Lodde BM; Szalayova I; Key S; Khalili S; Faustman DL; Mezey E
    Ann Rheum Dis; 2007 Jun; 66(6):812-4. PubMed ID: 17179174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sjögren's syndrome -- managing oral and systemic symptoms via a multi-disciplinary approach.
    Hamburger J
    Oral Dis; 2004 Sep; 10(5):306-9. PubMed ID: 15315649
    [No Abstract]   [Full Text] [Related]  

  • 24. Do we need new diagnostic criteria for Sjögren's syndrome?
    Daniels TE
    Presse Med; 2012 Sep; 41(9 Pt 2):e441-9. PubMed ID: 22840994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical evaluation of a commercially available oral moisturizer in relieving signs and symptoms of xerostomia in postirradiation head and neck cancer patients and patients with Sjögren's syndrome.
    Rhodus NL; Bereuter J
    J Otolaryngol; 2000 Feb; 29(1):28-34. PubMed ID: 10709169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of a sodium carbonate spray combined with professional oral hygiene procedures in patients with Sjögren's syndrome: an explorative study.
    Gambino A; Broccoletti R; Cafaro A; Cabras M; Carcieri P; Arduino PG
    Gerodontology; 2017 Jun; 34(2):208-214. PubMed ID: 27813150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Diagnostic and treatment considerations in sialosis].
    Lotreanu V; Sarafoleanu D; Trifan C
    Rev Chir Oncol Radiol O R L Oftalmol Stomatol Otorinolaringol; 1985; 30(2):135-7. PubMed ID: 3161142
    [No Abstract]   [Full Text] [Related]  

  • 28. [Salivary gland diseases].
    Gudziol H
    Ther Umsch; 1995 Nov; 52(11):774-9. PubMed ID: 7502256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sjögren's Syndrome: Oral Manifestations and Treatment, a Dental Perspective.
    Cartee DL; Maker S; Dalonges D; Manski MC
    J Dent Hyg; 2015 Dec; 89(6):365-71. PubMed ID: 26684993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sjögren's syndrome of the oral cavity. Review and update.
    Margaix-Muñoz M; Bagán JV; Poveda R; Jiménez Y; Sarrión G
    Med Oral Patol Oral Cir Bucal; 2009 Jul; 14(7):E325-30. PubMed ID: 19300364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sjögren's syndrome: the general dentist's role.
    Froeschle ML; Gobetti JP; Wuertz KM
    Chronicle; 1995 Oct; 58(6):90-1. PubMed ID: 9528485
    [No Abstract]   [Full Text] [Related]  

  • 32. Orofacial disease: update for the dental clinical team: 8. Salivary complaints.
    Scully C; Porter S
    Dent Update; 1999 Oct; 26(8):357-65. PubMed ID: 10765751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IL-17 sequestration via salivary gland gene therapy in a mouse model of Sjogren's syndrome suppresses disease-associated expression of the putative autoantigen Klk1b22.
    Wu C; Wang Z; Zourelias L; Thakker H; Passineau MJ
    Arthritis Res Ther; 2015 Aug; 17(1):198. PubMed ID: 26245278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment for salivary gland hypofunction at both initial and advanced stages of Sjögren-like disease: a comparative study of bone marrow therapy versus spleen cell therapy with a 1-year monitoring period.
    Khalili S; Faustman DL; Liu Y; Sumita Y; Blank D; Peterson A; Kodama S; Tran SD
    Cytotherapy; 2014 Mar; 16(3):412-23. PubMed ID: 24411591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral complications of Sjögren's syndrome.
    Napeñas JJ; Rouleau TS
    Oral Maxillofac Surg Clin North Am; 2014 Feb; 26(1):55-62. PubMed ID: 24287193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral manifestations and their treatment in Sjögren's syndrome.
    González S; Sung H; Sepúlveda D; González M; Molina C
    Oral Dis; 2014 Mar; 20(2):153-61. PubMed ID: 23557026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The use of plasmapheresis in treating Sjögren's disease (syndrome)].
    Gubin MA; Shcherbachenko OI; Lobodov BV
    Stomatologiia (Mosk); 1996; 75(3):24-6. PubMed ID: 9036579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of chronic sialadenitis in a murine model of Sjögren's syndrome by local fasL gene transfer.
    Fleck M; Zhang HG; Kern ER; Hsu HC; Müller-Ladner U; Mountz JD
    Arthritis Rheum; 2001 Apr; 44(4):964-73. PubMed ID: 11315936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome.
    Lodde BM; Mineshiba F; Wang J; Cotrim AP; Afione S; Tak PP; Baum BJ
    Ann Rheum Dis; 2006 Feb; 65(2):195-200. PubMed ID: 15975969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transfer of Sjögren's syndrome-like autoimmune lesions into SCID mice and prevention of lesions by anti-CD4 and anti-T cell receptor antibody treatment.
    Hayashi Y; Haneji N; Hamano H; Yanagi K
    Eur J Immunol; 1994 Nov; 24(11):2826-31. PubMed ID: 7957574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.